A deal for Forxiga should be lined up as well. IMO.
27 Aug 2019: AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Forxiga (dapagliflozin).The designation is for the indication of delaying the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease (CKD).
Where to from here?, page-22
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
87.0¢ |
Change
0.030(3.57%) |
Mkt cap ! $113.9M | |||
| Open | High | Low | Value | Volume |
| 84.0¢ | 87.0¢ | 82.5¢ | $144.3K | 170.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 82.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 87.0¢ | 14805 | 2 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |